Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Bros. Advisors Ups Stake in Seattle Genetics Inc. (SGEN)

Baker Bros. Advisors, managed by Julian Baker and Felix Baker, have disclosed raising its stake in Seattle Genetics Inc. (NASDAQ:SGEN). In a new filing with the U.S. Securities and Exchange Commission, Baker Bros. Advisors revealed that it brought the stake to 21.63 million shares, which represent 17.5% of common stock outstanding. In another filing, Baker Bros reported acquiring around 231,100 shares in market transactions and following conversion of stock options.

Seattle Genetics, Inc. (NASDAQ:SGEN)Felix J. Baker entered into a proceeds agreement with the fund on May 12, 2014, pursuant to the which he agreed that, with respect to the exercised stock options and the common stock received as a result of the exercise of the exercised stock options, the fund will have dispositive power as well as the ability to control the timing of exercise of the exercised stock options and that any proceeds from the sale of the common stock will be remitted to the fund net of brokerage commissions. Other than through their control of the fund, Baker and Julian C. Baker have neither voting nor dispositive power and have no direct pecuniary interest in the exercised stock options or the common stock.

Aside from Baker Bros, Jim Simons‘ Renaissance Technologies is another hedge fund bullish on Seattle Genetics. According to the fund’s latest 13F filing, Renaissance currently owns around 268,700 shares of the company, up by 142,700 shares in comparison to the previous filing. On the other hand, Israel Englander‘s Millennium Management significantly cut its stake in the company, by over 70%, to some 42,200 shares.

Baker Bros. Advisors focuses mainly on biotechnology companies. At the beginning of the year, the fund decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares from 1,130,317 shares revealed as held earlier.

Disclosure: none

Recommended Reading:

Hedge Fund Highlights: Chase Coleman, Daniel Loeb & David Tepper

Hedge Fund News: John Burbank, Phil Falcone & Jim Rogers

Julian Robertson Top Three Largest New Positions

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!